Open Journal Systems
Pharmacists' involvement in diabetic care: review of randomized controlled trials
Diabetes Mellitus (DM) is an emerging chronic disease with global implications. This article is a review of 35 RCTs to identify the potential benefits of pharmacists’ involvement in diabetic care in reducing the risk of diabetic complications and/or disease progression.
35 Randomized Controlled Trials (RCTs) were cherry-picked from 3210 publications listed on PubMed, using the following search keywords: diabetes, pharmacist, interventions and complications. Results of selected studies were analysed and interpreted.
Pharmacist-led program in diabetic patients significantly improved multiple outcomes such as patient’s quality of life, cost effectiveness in health care, medication adherence and clinical outcomes such as glycemic control, lipid profiles and blood pressure. Studies from different countries revealed similar results, confirming the universal value of pharmacists' involvement in diabetic care.
This review lays emphasis on the critical role of pharmacists in diabetic patient care. Pharmacists improve medication adherence, quality of life, health care cost-effectiveness in diabetic patients. These findings support the inevitable role of pharmacists in the collaborative diabetic care.
World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999. http://apps.who.int/iris/handle/10665/66040. Accessed April 28, 2019.
Roglic G. WHO Global report on diabetes: A summary. Int J Non-Commun Dis. 2016;1(1):3.
International Diabetes Federation. IDF Diabetes Atlas. 8th ed. Brussels, Belgium: International Diabetes Federation; 2018. http://www.idf.org/diabetesatlas. Accessed April 30, 2019.
Wiedenmayer K, Summers RS, Mackie CA, et al. Developing pharmacy practice: focus on patient care: Handbook. Geneva: World Health Organisation; 2006. http://www.who.int/medicines/publications/WHO_PSM_PAR_2006.5.pdf. Accessed May 2, 2019.
Mossialos E, Courtin E, Naci H, et al. From “retailers” to health care providers: transforming the role of community pharmacists in chronic disease management. Health policy. 2015;119(5):628-639. doi: 10.1016/j.healthpol.2015.02.007
Khanal S, Nissen L, Veerman L, Hollingworth S. Pharmacy workforce to prevent and manage non-communicable diseases in developing nations: The case of Nepal. Res Social Adm Pharm. 2016;12(4):655-659.
Deshpande PR, Vantipalli R, Lakshmi CC, et al. Clinical pharmacists: The major support to Indian healthcare system in near future. J Pharm Bioallied Sci. 2015;7(3):161-174.
Simpson SH, Lier DA, Majumdar SR, et al. Cost-effectiveness analysis of adding pharmacists to primary care teams to reduce cardiovascular risk in patients with Type 2 diabetes: results from a randomized controlled trial.Diabetic Med. 2015;32(7):899-906. doi: 10.1111/dme.12692.
Upadhyay DK, Ibrahim MI, Mishra P, Alurkar VM. A non-clinical randomised controlled trial to assess the impact of pharmaceutical care intervention on satisfaction level of newly diagnosed diabetes mellitus patients in a tertiary care teaching hospital in Nepal. BMC health serv. Res. 2015;15(1):57-67.
Wu WC, Taveira TH, Jeffery S, Jiang L, Tokuda L, Musial J, Cohen LB, Uhrle F. Costs and effectiveness of pharmacist-led group medical visits for type-2 diabetes: A multi-center randomized controlled trial. PLoS One. 2018;13(4):e0195898.
Wishah RA, Al-Khawaldeh OA, Albsoul AM. Impact of pharmaceutical care interventions on glycemic control and other health-related clinical outcomes in patients with type 2 diabetes: randomized controlled trial. Diabetes MetabSyndr. 2015;9(4):271-276.
Aguiar PM, da Silva CH, Chiann C, et al. Pharmacist–physician collaborative care model for patients with uncontrolled type 2 diabetes in Brazil: results from a randomized controlled trial. J Eval Clin Pract. 2018;24(1):22-30.
Kiel PJ, McCord AD. Pharmacist impact on clinical outcomes in a diabetes disease management program via collaborative practice. Ann Pharmacother. 2005;39(11):1828-1832.
Obreli-Neto PR, Guidoni CM, de Oliveira Baldoni A, et al. Effect of a 36-month pharmaceutical care program on pharmacotherapy adherence in elderly diabetic and hypertensive patients. Int Jof clin pharm. 2011;33(4):642-649.
Al Hamarneh YN, Hemmelgarn BR, Hassan I, Jones CA, Tsuyuki RT. The effectiveness of pharmacist interventions on cardiovascular risk in adult patients with type 2 diabetes: the multicentre randomized controlled RxEACH trial. Can J Diabetes. 2017;41(6):580-586.
Cohen LB, Taveira TH, Khatana SA, et al. Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes. Diabetes Educ. 2011;37(6):801-812.
Chan CW, Siu SC, Wong CK, Lee VW. A pharmacist care program: positive impact on cardiac risk in patients with type 2 diabetes. J Cardiovasc Pharmacol Ther. 2012;17(1):57-64.
Obarcanin E, Krüger M, Müller P, et al. Pharmaceutical care of adolescents with diabetes mellitus type 1: the DIADEMA study, a randomized controlled trial. Int J Clin Pharm. 2015;37(5):790-798.
Lim PC, Lim K, Embee ZC, et al. Study investigating the impact of pharmacist involvement on the outcomes of diabetes medication therapy adherence program Malaysia. Pak J Pharm Sci. 2016;29(2):595-601.
Anderegg MD, Gums TH, Uribe L, et al. Pharmacist intervention for blood pressure control in patients with diabetes and/or chronic kidney disease. Pharmacotherapy. 2018;38(3):309-318.
Bukhsh A, Nawaz MS, Ahmed HS, Khan TM. A randomized controlled study to evaluate the effect of pharmacist-led educational intervention on glycemic control, self-care activities and disease knowledge among type 2 diabetes patients. Med. 2018;97(12):e9847.
Jarab AS, Alqudah SG, Mukattash TL, Shattat G, Al-Qirim T. Randomized controlled trial of clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan. J Manag Care Pharm. 2012;18(7):516-526.
Venkatesan R, Devi AS, Parasuraman S, Sriram S. Role of community pharmacists in improving knowledge and glycemic control of type 2 diabetes. Perspect Clin Res. 2012;3(1):26-31.
Taveira TH, Dooley AG, Cohen LB, Khatana SA, Wu WC. Pharmacist-led group medical appointments for the management of type 2 diabetes with comorbid depression in older adults. Ann Pharmacother. 2011;45(11):1346-1355.
Al Mazroui NR, Kamal MM, Ghabash NM, et al. Influence of pharmaceutical care on health outcomes in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2009;67(5):547-557.
Ramanath KV, Santhosh YL. Impact of clinical pharmacist provided patient education on QOL outcome in type II diabetes mellitus in rural population. Asian J Pharm Clin Res. 2011;4(4):15-20.
Adibe MO, Ukwe CV, Aguwa CN. The impact of pharmaceutical care intervention on the quality of life of Nigerian patients receiving treatment for type 2 diabetes. Value Health Reg Issues. 2013;2(2):240-247.
Chen JH, Ou HT, Lin TC, Lai EC, Kao YH. Pharmaceutical care of elderly patients with poorly controlled type 2 diabetes mellitus: a randomized controlled trial. Int J Clin Pharm. 2016;38(1):88-95.
Adibe MO, Aguwa CN, Ukwe CV. Cost-utility analysis of pharmaceutical care intervention versus usual care in management of Nigerian patients with type 2 diabetes. Value Health Reg Issues. 2013;2(2):189-198.
Mehuys E, Van Bortel L, De Bolle L, et al. Effectiveness of a community pharmacist intervention in diabetes care: a randomized controlled trial. J Clin Pharm Ther. 2011;36(5):602-613.
Hendrie D, Miller TR, Woodman RJ, Hoti K, Hughes J. Cost-effectiveness of reducing glycaemic episodes through community pharmacy management of patients with type 2 diabetes mellitus. J Prim Prev. 2014;65(6):439-449.
Siaw MY, Ko Y, Malone DC, et al. Impact of pharmacist‐involved collaborative care on the clinical, humanistic and cost outcomes of high‐risk patients with type 2 diabetes (IMPACT): a randomized controlled trial. J Clin Pharm and Ther. 2017;42(4):475-482.
Kjeldsen LJ, Bjerrum L, Dam P, et al. Safe and effective use of medicines for patients with type 2 diabetes: a randomized controlled trial of two interventions delivered by local pharmacies. Res Social Adm Pharm. 2015;11(1):47-62.
Korcegez EI, Sancar M, Demirkan K. Effect of a pharmacist-led program on improving outcomes in patients with type 2 diabetes mellitus from Northern Cyprus: a randomized controlled trial. J Manag care Spec pharm. 2017;23(5):573-582.
Plaster CP, Melo DT, Boldt V, et al. Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up. Braz J Pharm Sci. 2012;48(3):435-446.
Ali M, Schifano F, Robinson P, et al. Impact of community pharmacy diabetes monitoring and education programme on diabetes management: a randomized controlled study.Diabet Med. 2012;29(9):e326-333.
Adepu SP, Ramanath KV, Bhat S, Sam S, Omanakuttan C. Assessment of Pharmacist-Mediated Education on Medication Adherence Behaviour in Type 2 Diabetes Mellitus Patients. Value Health. 2016;19(3):A18.
Michiels Y, Bugnon O, Chicoye A, et al. Impact of a Community Pharmacist-Delivered Information Program on the Follow-up of Type-2 Diabetic Patients: A Cluster Randomized Controlled Study. Adv Ther. 2019;36(6):1291-1303.
Chung WW, Chua SS, Lai PS, Chan SP. Effects of a pharmaceutical care model on medication adherence and glycemic control of people with type 2 diabetes. Patient Prefer Adher. 2014;8:1185-1194.doi: 10.2147/PPA.S66619.
Farsaei S, Sabzghabaee AM, Zargarzadeh AH, Amini M. Effect of pharmacist-led patient education on glycemic control of type 2 diabetics: a randomized controlled trial. J Res Med Sci. 2011;16(1):43-49.
Cohen HW, Shmukler C, Ullman R, Rivera CM, Walker EA. Measurements of medication adherence in diabetic patients with poorly controlled HbA1c. Diabetic Medicine. 2010;27(2):210-216.
Gonzalez JS, Schneider HE, Wexler DJ, et al. Validity of medication adherence self-reports in adults with type 2 diabetes. Diabetes Care. 2013;36(4):831-837.